Outcomes of Nontransitioned Cases in a Sample at Ultra-High Risk for Psychosis
Ashleigh Lin, Stephen J Wood, Barnaby Nelson, Amanda Beavan, Patrick McGorry, Alison R Yung
AMERICAN JOURNAL OF PSYCHIATRY | AMER PSYCHIATRIC PUBLISHING, INC | Published : 2015
OBJECTIVE: Two-thirds of individuals identified as at ultra-high risk for psychosis do not develop psychotic disorder over the medium term. The authors examined outcomes in a group of such patients. METHOD: Participants were help-seeking individuals identified as being at ultra-high risk for psychosis 2-14 years previously. The 226 participants (125 female, 101 male) completed a follow-up assessment and had not developed psychosis. Their mean age at follow-up was 25.5 years (SD=4.8). RESULTS: At follow-up, 28% of the participants reported attenuated psychotic symptoms. Over the follow-up period, 68% experienced nonpsychotic disorders: mood disorder in 49%, anxiety disorder in 35%, and substa..View full abstract
Related Projects (4)
Awarded by National Health and Medical Research Council (NHMRC)
Supported by National Health and Medical Research Council (NHMRC) program grants (350241 and 566529) to Drs. Yung, Wood, and McGorry, by the Colonial Foundation, and by an unrestricted research grant from Janssen-Cilag. Dr. Wood was supported by NHMRC Career Development Awards. Dr. Nelson was supported by a Ronald Phillip Griffith Fellowship and an NHMRC Career Development Fellowship. Dr. Yung is the recipient of a NHMRC Senior Research Fellowship. Dr. Lin is supported by an NHMRC Early Career Fellowship. No funding source played any role in the collection, analysis, interpretation, or publication of data. The authors thank Miss Sandra Para Bartolome for assistance with data processing.Dr. McGorry currently receives research support from the National Health and Medical Research Council of Australia and the Colonial Foundation; he has also received grant funding from NARSAD and unrestricted research funding from AstraZeneca, Eli Lilly, Janssen-Cilag, Pfizer, and Novartis, as well as honoraria for educational activities with AstraZeneca, Eli Lilly, Janssen-Cilag, Pfizer, Bristol-Myers Squibb, Roche, and the Lundbeck Institute. Dr. Yung has received an unrestricted research grant from Janssen Cilag and honoraria from Janssen Cilag and Autifony Therapeutics. The other authors report no financial relationships with commercial interests.